KINTARA THERAPEUTICS INC (KTRA)

US49720K2006 - Common Stock

0.2154  -0.01 (-6.31%)

After market: 0.225 +0.01 (+4.46%)

KINTARA THERAPEUTICS INC

NASDAQ:KTRA (10/17/2024, 8:46:26 PM)

After market: 0.225 +0.01 (+4.46%)

0.2154

-0.01 (-6.31%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%97.86%
Sales Q2Q%N/A
CRS3.71
6 Month77.43%
Overview
Earnings (Last)10-09 2024-10-09/amc
Earnings (Next)11-11 2024-11-11/amc
Ins Owners5.59%
Inst Owners1.51%
Market Cap11.99M
Shares55.66M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts43.33
Short Float %N/A
Short RatioN/A
IPO07-12 2016-07-12
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

KTRA Daily chart

Company Profile

Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. The company is headquartered in San Diego, California and currently employs 2 full-time employees. The company went IPO on 2016-07-12. The firm's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). REM-001, is a late-stage photodynamic therapy (PDT). PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of reactive oxygen that induces local tumor cell death. The company has a proprietary, late-stage photodynamic therapy platform. REM-001 Therapy consists of the laser light source, the light delivery device, and the REM-001 drug product. Its product candidate, VAL-083, is a DNA-targeting agent intended to treat drug-resistant solid tumors, such as glioblastoma (GBM) and potentially other smaller tumors, from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study. VAL-083 is also used for various other indications.

Company Info

KINTARA THERAPEUTICS INC

9920 Pacific Heights Blvd, Suite 150, Suite 200

San Diego CALIFORNIA 92130

P: 18583504364

CEO: Saiid Zarrabian

Employees: 2

Website: https://www.kintara.com/

KTRA News

News Image2 months ago - Kintara TherapeuticsKintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

/PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer...

News Image2 months ago - Kintara TherapeuticsKintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

/PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer...

News Image2 months ago - Kintara TherapeuticsKintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

/PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer...

News Image2 months ago - Kintara TherapeuticsKintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

/PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer...

News Image2 months ago - Kintara TherapeuticsKintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

News Image3 months ago - Kintara TherapeuticsKintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer...

KTRA Twits

Here you can normally see the latest stock twits on KTRA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example